EA
SUPN icon

Emerald Acquisition’s Supernus Pharmaceuticals SUPN Stock Holding History

Emerald Acquisition’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$20.6M Buy
832,959
+115,736
+16% +$2.62M 0.04% 513
2016
Q2 		$14.6M Buy
+717,223
New +$12.7M 0.03% 728

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's SUPN Position: Q3 2016 in Review

Emerald Acquisition increased its Supernus Pharmaceuticals (SUPN) stake by 16% in Q3 2016, buying an estimated $2.62M and bringing the position to 832,959 shares worth $20.6M. The position accounts for 0.04% of the portfolio, ranked #513.

Emerald Acquisition first reported a position in SUPN in Q2 2016 and has held it in 2 quarters since. 221 funds tracked by Wall St. Rank hold SUPN as of Q3 2016.

  • Emerald Acquisition held 832,959 shares of Supernus Pharmaceuticals worth $20.6M as of Q3 2016.
  • Emerald Acquisition bought 115,736 Supernus Pharmaceuticals shares in Q3 2016, an estimated $2.62M.
  • Supernus Pharmaceuticals made up 0.04% of Emerald Acquisition's portfolio in Q3 2016, its #513 holding.
  • Emerald Acquisition first reported a position in Supernus Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 221 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.